Start here if you're new
what it is
BioCryst sells rare-disease drugs, led by a daily pill that helps prevent hereditary swelling attacks.
how it gets paid
Last year Biocryst Pharm made $875M in revenue.
why it's growing
Revenue grew 94.1% last year. $468M matters most because it is more than the $451M full-year revenue estimate on its own.
what just happened
Latest quarter revenue hit $468M, up 194% vs. prior year, while EPS turned positive at $0.08.
At a glance
B balance sheet — gets the job done, barely
40/100 earnings predictability — expect surprises
0.6x trailing p/e — the market's not buying it — or you found a deal
-$0.43 fy2024 eps est
$451M fy2024 rev est
xvary composite: 34/100 — weak
What they do
BioCryst sells rare-disease drugs, led by a daily pill that helps prevent hereditary swelling attacks.
ORLADEYO is once-daily and oral. That matters when your alternative can mean injections, clinic visits, or both. BioCryst has 580 employees supporting a rare-disease business built around making prevention easier to live with, and easier for your doctor to keep prescribing.
How they make money
$875M
annual revenue · their business grew +94.1% last year
total revenue
$875M
+94.1%
The products that matter
approved commercial product
Orladeyo
$875M · primary revenue engine
It's the drug doing the heavy lifting. When one product is attached to $875M in revenue, every prescription trend matters more than management slides do.
the business today
development-stage pipeline
BCX10013 pipeline
no revenue disclosed here
This is the option value. At a roughly $2B market cap, the pipeline still matters, but this snapshot does not give enough data to treat it like a proven second engine.
the upside case
capital structure reality
balance sheet
$644M debt · B grade
Biotech stories get less forgiving when debt shows up. A B balance sheet is workable, but it gives you less room for commercial stumbles.
constraint
Key numbers
-$0.43
fy2024 eps est
$451M
fy2024 rev est
0.6x
trailing p/e
n/a
dividend yield
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 10 / 100
- long-term debt $644M (24% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for BCRX right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Latest quarter revenue hit $468M, up 194% vs. prior year, while EPS turned positive at $0.08.
That is the clean contrast. Quarterly numbers finally look like a profitable company, while the full-year estimate still points to a loss. You are buying the gap between those two realities.
$468M
revenue
$0.08
eps
+194%
revenue growth
the number that mattered
$468M matters most because it is more than the $451M full-year revenue estimate on its own, which tells you the data set is messy or the business just changed fast.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is Orladeyo concentration risk. When one product carries most of the visible commercial story, everything else becomes a second-order effect until proven otherwise.
high
Revenue quality gap
Two credible data sets are telling very different stories. EDGAR shows $875M of annual revenue, while another widely used estimate shows $451M for FY2024.
That is a $424M gap, or about 48% of the EDGAR total, and it changes how you should value the stock.
med
Debt before consistency
Long-term debt is $644M, equal to 24% of capital. That is manageable if quarterly profit sticks, and annoying if revenue normalizes lower.
A weaker sales base could leave debt equal to more than 1.4x the $451M revenue estimate.
med
One-drug dependence
The business narrative still runs through ORLADEYO. RAPIVAB exists, but the moat story is really about one rare-disease franchise.
If ORLADEYO stalls, you are not trimming a side business. You are threatening the majority of a company worth about $2B.
A stall in the core product would pressure the visible revenue base while the company still carries $644M in long-term debt. That is why this remains a high-execution story despite the takeover narrative.
source: institutional data · regulatory filings · risk analysis
Pay attention to
next report
April 30, 2026 is the next reality check
The street expects $0.06 EPS. More important than the penny count: whether management sounds like it can grow the existing revenue base without leaning on rumor.
core metric
Orladeyo still has to justify being the whole story
With $875M tied to one commercial engine, you are not looking for cute pipeline language. You are looking for proof that the main asset keeps doing the heavy lifting.
risk
Takeover premium can vanish faster than it appeared
The recent 15% move came from chatter. If no strategic buyer materializes, the stock goes back to being judged on operations, debt, and concentration risk.
execution
The new CEO needs an early credibility win
Leadership transitions are easiest when the core asset is accelerating. They get much harder when the company is already being asked to defend one-drug dependence.
Analyst rankings
earnings predictability
40 / 100
in human-speak, quarterly outcomes can still surprise you.
price stability
10 / 100
this is a volatile stock. if you own it, expect wide swings.
risk rank
4
on a 1-to-5 scale, this sits on the riskier side. safer than 20% of stocks is not a compliment.
coverage depth
thin
this data cut does not include a full target stack, so the operating numbers matter more than consensus theater.
source: institutional data
Institutional activity
institutional ownership data for BCRX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive